Cargando…

Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study

Background and objectives: Because few data are available, the aim of this study is to analyze the effects of antithrombotic agents (ATAs) on visual function and long-term risk of cardiovascular events and mortality in hypertensive patients with retinal vein occlusion (RVO). Materials and methods: H...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoli, Federica, Bais, Bruno, De Silvestri, Daniele, Mariotti, Barbara, Veritti, Daniele, Cavarape, Alessandro, Catena, Cristiana, Lanzetta, Paolo, Sechi, Leonardo Alberto, Colussi, GianLuca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537937/
https://www.ncbi.nlm.nih.gov/pubmed/34684054
http://dx.doi.org/10.3390/medicina57101017
_version_ 1784588387688120320
author Bertoli, Federica
Bais, Bruno
De Silvestri, Daniele
Mariotti, Barbara
Veritti, Daniele
Cavarape, Alessandro
Catena, Cristiana
Lanzetta, Paolo
Sechi, Leonardo Alberto
Colussi, GianLuca
author_facet Bertoli, Federica
Bais, Bruno
De Silvestri, Daniele
Mariotti, Barbara
Veritti, Daniele
Cavarape, Alessandro
Catena, Cristiana
Lanzetta, Paolo
Sechi, Leonardo Alberto
Colussi, GianLuca
author_sort Bertoli, Federica
collection PubMed
description Background and objectives: Because few data are available, the aim of this study is to analyze the effects of antithrombotic agents (ATAs) on visual function and long-term risk of cardiovascular events and mortality in hypertensive patients with retinal vein occlusion (RVO). Materials and methods: Hypertensive patients with RVO were consecutively selected from 2008 to 2012 and followed for a median of 8.7 years. Ophthalmologists evaluated and treated RVO complications, and best-corrected visual acuity (BCVA) was checked at each visit during the first one year of follow-up. Survival analysis was conducted on the rate of the composite endpoint of all-cause deaths or non-fatal cardiovascular events. Results: Retrospectively, we collected data from 80 patients (age 68 ± 12 years, 39 males). Central and branch RVO was present in 41 and 39 patients, respectively, and 56 patients started ATAs (50 antiplatelet drugs, 6 warfarin, and 2 low-molecular weight heparin). Average BCVA of the cohort did not change significantly during one-year of follow-up. The only predictor of BCVA was the baseline BCVA value. There was a reduction in proportion and severity of macular edema and an increase in the cumulative proportion of retinal vein patency reestablishment during the follow-up, independent of treatment. ATAs had no effects on one-year BCVA, intraocular complications, or the composite endpoint rate. Conclusions: In this exploratory study, ATAs had no effect on BCVA during the first one year of follow-up and on the composite endpoint during the long-term follow-up. Further prospective studies need to be conducted with an accurate standardization of the intraocular and antithrombotic treatment to define the positive or negative role of ATAs in hypertensive patients with RVO.
format Online
Article
Text
id pubmed-8537937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85379372021-10-24 Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study Bertoli, Federica Bais, Bruno De Silvestri, Daniele Mariotti, Barbara Veritti, Daniele Cavarape, Alessandro Catena, Cristiana Lanzetta, Paolo Sechi, Leonardo Alberto Colussi, GianLuca Medicina (Kaunas) Article Background and objectives: Because few data are available, the aim of this study is to analyze the effects of antithrombotic agents (ATAs) on visual function and long-term risk of cardiovascular events and mortality in hypertensive patients with retinal vein occlusion (RVO). Materials and methods: Hypertensive patients with RVO were consecutively selected from 2008 to 2012 and followed for a median of 8.7 years. Ophthalmologists evaluated and treated RVO complications, and best-corrected visual acuity (BCVA) was checked at each visit during the first one year of follow-up. Survival analysis was conducted on the rate of the composite endpoint of all-cause deaths or non-fatal cardiovascular events. Results: Retrospectively, we collected data from 80 patients (age 68 ± 12 years, 39 males). Central and branch RVO was present in 41 and 39 patients, respectively, and 56 patients started ATAs (50 antiplatelet drugs, 6 warfarin, and 2 low-molecular weight heparin). Average BCVA of the cohort did not change significantly during one-year of follow-up. The only predictor of BCVA was the baseline BCVA value. There was a reduction in proportion and severity of macular edema and an increase in the cumulative proportion of retinal vein patency reestablishment during the follow-up, independent of treatment. ATAs had no effects on one-year BCVA, intraocular complications, or the composite endpoint rate. Conclusions: In this exploratory study, ATAs had no effect on BCVA during the first one year of follow-up and on the composite endpoint during the long-term follow-up. Further prospective studies need to be conducted with an accurate standardization of the intraocular and antithrombotic treatment to define the positive or negative role of ATAs in hypertensive patients with RVO. MDPI 2021-09-25 /pmc/articles/PMC8537937/ /pubmed/34684054 http://dx.doi.org/10.3390/medicina57101017 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bertoli, Federica
Bais, Bruno
De Silvestri, Daniele
Mariotti, Barbara
Veritti, Daniele
Cavarape, Alessandro
Catena, Cristiana
Lanzetta, Paolo
Sechi, Leonardo Alberto
Colussi, GianLuca
Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
title Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
title_full Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
title_fullStr Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
title_full_unstemmed Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
title_short Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
title_sort effects of antithrombotic agents on ophthalmological outcomes, cardiovascular risk, and mortality in hypertensive patients with retinal vein occlusion: an exploratory retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537937/
https://www.ncbi.nlm.nih.gov/pubmed/34684054
http://dx.doi.org/10.3390/medicina57101017
work_keys_str_mv AT bertolifederica effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT baisbruno effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT desilvestridaniele effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT mariottibarbara effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT verittidaniele effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT cavarapealessandro effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT catenacristiana effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT lanzettapaolo effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT sechileonardoalberto effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy
AT colussigianluca effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy